VAP - Ventilator Associated Pneumonia Clinical Trial
Official title:
Safety and Efficiency of the Prolonged (72-hour) Use of a Single Heat and Moisture Exchanger in Adult Mechanically Ventilated Critically Ill and Its Impact on the Lower Respiratory Tract Pathogenic Microbial Colonisation Rate (FILTRex Trial); a Single-centre, Randomised, Controlled Trial
FILTRex is a single-centre, controlled, randomised, prospective, non-inferiority clinical trial to compare the efficiency and safety of prolonged (72-hours) versus standard (24-hours) duration of use for Heat and Moisture Exchange (HME) filters in adult mechanically ventilated critically ill patients
Rationale: Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection (HAI) in the intensive care unit (ICU), and its impact is very high in terms of morbidity, length of hospital stay and overall costs. Minimising manipulation and disconnection of the ventilator circuit by reducing the frequency of HME filter exchange may lower the risk of its secondary contamination, hence the incidence of VAP, while maintaining its efficacy in terms of sufficient humidification of the inhaled gas mixture and safety in terms of no or minimal change in resistance to airflow. Aim: To test the effectiveness and safety of prolonged (72-hour exchange interval) use of a single HME. Design: Prospective, single-centre, parallel-group randomised controlled trial. Subjects: ICU patients (general ICU) Treatment in the intervention group: HME filter exchange every 72 hours Control group: Standard-of-care: daily HME filter exchange Primary outcome: 1. Presence of HME-associated adverse events (a composite endpoint of endotracheal tube occlusion or nosocomial tracheobronchitis or pneumonia). 2. The cumulative incidence of lower respiratory tract microbial colonisation analysed by the Kaplan-Maier method, censored in the case of ICU discharge or extubation > 24h. Secondary and exploratory outcomes: Differences in the relative risk of infection-related ventilator-associated complications, antibiotics (ATB) exposure analysis, length of ICU stay in days (time frame: three months), number of ventilator-free days (time frame: 28 days); differences in the incidence of endotracheal tube occlusion necessitating reintubation between individual groups, differences in airway resistance, humidity delivered to the patients and efficacy of HMEs between groups ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05575050 -
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
|
N/A | |
| Not yet recruiting |
NCT06035796 -
Performance Study of Targeted Sequencing Technology for VAP
|
||
| Not yet recruiting |
NCT06073834 -
LUNG INFECTION IN ICU (LUNG-I3)
|
||
| Not yet recruiting |
NCT06045429 -
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
|
Phase 4 | |
| Not yet recruiting |
NCT04955821 -
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
|
||
| Completed |
NCT04038814 -
The Effectiveness of the Modified Bundle in the Prevention of VAP.
|
||
| Completed |
NCT05230472 -
Effect of Statin Therapy on Mortality in Patients With Ventilator Associated Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT05738928 -
Microbiological Profile of VAP Patients in Respiratory ICU
|
||
| Completed |
NCT05176353 -
Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial
|
N/A | |
| Recruiting |
NCT05952648 -
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
|
N/A |